We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$580M
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
-1.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$210M
AUM Growth
-$22.7M
(-9.8%)
Cap. Flow
+$4.13M
Cap. Flow
% of AUM
1.97%
Top 10 Holdings %
Top 10 Hldgs %
48.59%
Holding
65
New
13
Increased
16
Reduced
18
Closed
18
Avg Time Held Equity + Options
3
quarters
Top 10 Avg Time Held Equity + Options
1.7
quarters
Top 20 Avg Time Held Equity + Options
3.6
quarters
Avg Time Held Equity only
3.2
quarters
Top 10 Avg Time Held Equity only
1.8
quarters
Top 20 Avg Time Held Equity only
3.7
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cue Biopharma
CUE
|
+$7.68M |
| 2 |
Aurinia Pharmaceuticals
AUPH
|
+$7.29M |
| 3 |
Baxter International
BAX
|
+$6.69M |
| 4 |
Prothena Corp
PRTA
|
+$6.56M |
| 5 |
MTCR
Metacrine, Inc. Common Stock
MTCR
|
+$5.31M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kura Oncology
KURA
|
+$12.8M |
| 2 |
Arrowhead Research
ARWR
|
+$4.93M |
| 3 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$4.28M |
| 4 |
Aldeyra Therapeutics
ALDX
|
+$3.41M |
| 5 |
Vericel Corp
VCEL
|
+$2.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.06% |
| 2 | Technology | 4.31% |
| 3 | Miscellaneous | 3.63% |
| 4 | Energy | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
ALXN
1
DELISTED
Alexion Pharmaceuticals
ALXN
| $13.3M | 6.3% |
115,800
+25,800
| +29% | +$2.78M |
2020 Q1
2 quarters
|
|
|
ARNA
2
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $12.2M | 5.8% |
163,057
-64,155
| -28% | -$4.28M |
2018 Q1
10 quarters
|
|
3
Bristol-Myers Squibb
BMY
$116B
| $11.2M | 5.32% |
185,500
+67,500
| +57% | +$4.06M |
2020 Q2
1 quarter
|
|
|
RETA
4
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $11.2M | 5.31% |
114,554
+32,454
| +40% | +$4.06M |
2017 Q4
11 quarters
|
|
|
5
Cue Biopharma
CUE
$142M
| $10.7M | 5.08% |
23,665
+13,322
| +129% | +$7.68M |
2019 Q4
3 quarters
|
|
|
6
Baxter International
BAX
$12.9B
| $9.81M | 4.67% |
122,000
+79,500
| +187% | +$6.69M |
2020 Q2
1 quarter
|
|
|
CHNG
7
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $9.06M | 4.31% |
624,200
-205,900
| -25% | -$2.62M |
2020 Q1
2 quarters
|
|
|
8
Aurinia Pharmaceuticals
AUPH
$2.18B
| $8.76M | 4.17% |
595,000
+503,000
| +547% | +$7.29M |
2020 Q2
1 quarter
|
|
|
9
Aldeyra Therapeutics
ALDX
$54.3M
| $8.09M | 3.85% |
1,092,000
-528,200
| -33% | -$3.41M |
2018 Q4
7 quarters
|
|
10
Cigna
CI
$74.7B
| $7.96M | 3.79% |
47,000
+8,500
| +22% | +$1.5M |
2018 Q1
10 quarters
|
|
11
Encompass Health
EHC
$12.3B
| $7.01M | 3.34% |
135,657
+94,302
| +228% | +$4.84M |
2020 Q1
2 quarters
|
|
12
Centene
CNC
$34B
| $6.88M | 3.27% |
117,935
-41,765
| -26% | -$2.59M |
2017 Q4
11 quarters
|
|
|
APTO
13
DELISTED
Aptose Biosciences, Inc.
APTO
| $6.83M | 3.25% |
2,531
+791
| +45% | +$1.97M |
2020 Q2
1 quarter
|
|
14
Zimmer Biomet
ZBH
$17.6B
| $6.62M | 3.15% |
50,058
-20,497
| -29% | -$2.68M |
2018 Q3
8 quarters
|
|
15
uniQure
QURE
$1.48B
| $6.31M | 3% |
171,429
+28,300
| +20% | +$1.16M |
2019 Q2
5 quarters
|
|
|
16
Prothena Corp
PRTA
$429M
| $5.45M | 2.59% |
+545,195
| New | +$6.56M |
2020 Q3
0 quarters
|
|
|
MTCR
17
DELISTED
Metacrine, Inc. Common Stock
MTCR
| $5.3M | 2.52% |
+518,796
| New | +$5.31M |
2020 Q3
0 quarters
|
|
18
MeiraGTx Holdings
MGTX
$955M
| $5.18M | 2.46% |
391,099
-128,868
| -25% | -$1.7M |
2019 Q3
4 quarters
|
|
19
AC Immune
ACIU
$239M
| $4.5M | 2.14% |
923,117
-253,684
| -22% | -$1.82M |
2019 Q1
6 quarters
|
|
|
ALBO
20
DELISTED
Albireo Pharma Inc
ALBO
| $4.09M | 1.94% |
122,500
-76,300
| -38% | -$2.22M |
2018 Q3
8 quarters
|
|
21
Iovance Biotherapeutics
IOVA
$6.57B
| $3.97M | 1.89% |
120,606
-94,394
| -44% | -$2.89M |
2017 Q4
11 quarters
|
|
|
ALXN
22
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
| $3.89M | 1.85% |
+34,000
| New | +$3.67M |
2020 Q3
0 quarters
|
|
23
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $3.84M | 1.83% |
282,100
+192,590
| +215% | +$2.97M |
2020 Q2
1 quarter
|
|
24
PUT
iShares S&P 100 ETF
OEF
$20.8B
| $3.6M | 1.71% |
24,000
-171,000
| -88% | -$26.3M |
2020 Q2
1 quarter
|
|
25
Cellectis
CLLS
$111M
| $3.43M | 1.63% |
185,180
-91,397
| -33% | -$1.62M |
2020 Q2
1 quarter
|
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q3 2020 Portfolio in Review
As of Q3 2020, Prosight Management held 65 positions worth $210M, down 9.8% from $233M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Prosight Management's Q3 2020 filing shows 13 new, 16 increased, 18 reduced and 18 closed positions. Its largest new stake was Prothena Corp: 545,195 shares worth $5.45M. The largest sale was Kura Oncology, an estimated $12.8M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 82% a quarter earlier, followed by Technology and Miscellaneous.
- Prosight Management's largest Q3 2020 buy was Prothena Corp: 545,195 shares worth $5.45M.
- Prosight Management added most to Cue Biopharma in Q3 2020, an estimated $7.68M increase.
- Prosight Management's biggest Q3 2020 reduction was Kura Oncology, cutting an estimated $12.8M.
- Prosight Management fully exited Arrowhead Research in Q3 2020, selling an estimated $4.93M.
- Prosight Management's ten largest holdings make up 49% of its $210M portfolio in Q3 2020.
- Prosight Management opened 13 new positions and closed 18 in Q3 2020.
- Prosight Management's portfolio value fell 9.8% quarter-over-quarter to $210M.
Based on Prosight Management's 13F filing for Q3 2020, filed 13 Nov 2020.